Cargando…
Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1
Treatment of type 1 diabetes mellitus (T1D) in children and adolescents is complex and a challenge for the children and adolescents themselves, their families, and their whole environment (schools/kindergartens). The aim of the diabetes therapy is to achieve near-normoglycemic glucose values and to...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643949/ http://dx.doi.org/10.1007/s11428-022-00975-5 |
_version_ | 1784826634623254528 |
---|---|
author | Rami-Merhar, Birgit |
author_facet | Rami-Merhar, Birgit |
author_sort | Rami-Merhar, Birgit |
collection | PubMed |
description | Treatment of type 1 diabetes mellitus (T1D) in children and adolescents is complex and a challenge for the children and adolescents themselves, their families, and their whole environment (schools/kindergartens). The aim of the diabetes therapy is to achieve near-normoglycemic glucose values and to prevent acute and chronic complications. Further aims are normal development, inclusion, flexibility in everyday life, and a high quality of live. Apart from newer insulin analogues, diabetes technology has changed and improved diabetes therapy and the quality of life of affected families. The usage of insulin pumps—continuous insulin infusion, continuous subcutaneous glucose monitoring, and automated insulin dosing (AID) has led to significant improvement in metabolic control, a reduction of severe hypoglycemia and diabetic ketoacidosis. Diabetes technology is constantly evolving and necessitates comprehensive continuing education of the families, the school/kindergarten teams, as well as the multidisciplinary team of healthcare professionals. The intention is a reduction of glycemic variability and a better long-term outcome in young people with T1D. AID is increasingly becoming the therapy of choice in children and adolescents with T1D. Further innovations in diabetes technology can be expected for the near future. |
format | Online Article Text |
id | pubmed-9643949 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-96439492022-11-14 Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 Rami-Merhar, Birgit Diabetologie Leitthema Treatment of type 1 diabetes mellitus (T1D) in children and adolescents is complex and a challenge for the children and adolescents themselves, their families, and their whole environment (schools/kindergartens). The aim of the diabetes therapy is to achieve near-normoglycemic glucose values and to prevent acute and chronic complications. Further aims are normal development, inclusion, flexibility in everyday life, and a high quality of live. Apart from newer insulin analogues, diabetes technology has changed and improved diabetes therapy and the quality of life of affected families. The usage of insulin pumps—continuous insulin infusion, continuous subcutaneous glucose monitoring, and automated insulin dosing (AID) has led to significant improvement in metabolic control, a reduction of severe hypoglycemia and diabetic ketoacidosis. Diabetes technology is constantly evolving and necessitates comprehensive continuing education of the families, the school/kindergarten teams, as well as the multidisciplinary team of healthcare professionals. The intention is a reduction of glycemic variability and a better long-term outcome in young people with T1D. AID is increasingly becoming the therapy of choice in children and adolescents with T1D. Further innovations in diabetes technology can be expected for the near future. Springer Medizin 2022-11-08 2022 /pmc/articles/PMC9643949/ http://dx.doi.org/10.1007/s11428-022-00975-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Leitthema Rami-Merhar, Birgit Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title | Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title_full | Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title_fullStr | Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title_full_unstemmed | Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title_short | Diabetestechnologie bei Kindern und Jugendlichen mit Diabetes mellitus Typ 1 |
title_sort | diabetestechnologie bei kindern und jugendlichen mit diabetes mellitus typ 1 |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643949/ http://dx.doi.org/10.1007/s11428-022-00975-5 |
work_keys_str_mv | AT ramimerharbirgit diabetestechnologiebeikindernundjugendlichenmitdiabetesmellitustyp1 |